why choose us

First received: August 12, 2022

Clinical Trial: Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Study Status: ACTIVE_NOT_RECRUITING

Recruit Status: ACTIVE_NOT_RECRUITING

Condition: Allogeneic Hematopoietic Cell Transplantation

Study Type: INTERVENTIONAL


Official Title: Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation in Non-Malignant Diseases

Brief Summary: Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT).In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the level of Day 0 (the planned day of graft infusion) to an optimal therapeutic window of 0.2-0.6 ug/mL.

Read more